| Product Code: ETC7730691 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Japan Acute Myeloid Testing Market Overview |
3.1 Japan Country Macro Economic Indicators |
3.2 Japan Acute Myeloid Testing Market Revenues & Volume, 2021 & 2031F |
3.3 Japan Acute Myeloid Testing Market - Industry Life Cycle |
3.4 Japan Acute Myeloid Testing Market - Porter's Five Forces |
3.5 Japan Acute Myeloid Testing Market Revenues & Volume Share, By Biomarker Type, 2021 & 2031F |
3.6 Japan Acute Myeloid Testing Market Revenues & Volume Share, By Product and Service, 2021 & 2031F |
3.7 Japan Acute Myeloid Testing Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.8 Japan Acute Myeloid Testing Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Japan Acute Myeloid Testing Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of acute myeloid leukemia (AML) in Japan |
4.2.2 Technological advancements in diagnostic testing methods for AML |
4.2.3 Growing awareness about the importance of early detection and diagnosis of AML |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for diagnostic testing in Japan |
4.3.2 Limited reimbursement policies for AML testing |
4.3.3 High cost associated with advanced AML testing technologies |
5 Japan Acute Myeloid Testing Market Trends |
6 Japan Acute Myeloid Testing Market, By Types |
6.1 Japan Acute Myeloid Testing Market, By Biomarker Type |
6.1.1 Overview and Analysis |
6.1.2 Japan Acute Myeloid Testing Market Revenues & Volume, By Biomarker Type, 2021- 2031F |
6.1.3 Japan Acute Myeloid Testing Market Revenues & Volume, By Proteomic AML Biomarker, 2021- 2031F |
6.1.4 Japan Acute Myeloid Testing Market Revenues & Volume, By Genetic AML Biomarker, 2021- 2031F |
6.1.5 Japan Acute Myeloid Testing Market Revenues & Volume, By Epigenetic AML Biomarker, 2021- 2031F |
6.2 Japan Acute Myeloid Testing Market, By Product and Service |
6.2.1 Overview and Analysis |
6.2.2 Japan Acute Myeloid Testing Market Revenues & Volume, By Services, 2021- 2031F |
6.2.3 Japan Acute Myeloid Testing Market Revenues & Volume, By Assay Kits, 2021- 2031F |
6.3 Japan Acute Myeloid Testing Market, By Technology |
6.3.1 Overview and Analysis |
6.3.2 Japan Acute Myeloid Testing Market Revenues & Volume, By PCR, 2021- 2031F |
6.3.3 Japan Acute Myeloid Testing Market Revenues & Volume, By IHC, 2021- 2031F |
6.3.4 Japan Acute Myeloid Testing Market Revenues & Volume, By NGS, 2021- 2031F |
6.3.5 Japan Acute Myeloid Testing Market Revenues & Volume, By Cytogenetics, 2021- 2031F |
6.3.6 Japan Acute Myeloid Testing Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Japan Acute Myeloid Testing Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Japan Acute Myeloid Testing Market Revenues & Volume, By Clinical Laboratories, 2021- 2031F |
6.4.3 Japan Acute Myeloid Testing Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.4 Japan Acute Myeloid Testing Market Revenues & Volume, By Academic and Research Institutes, 2021- 2031F |
6.4.5 Japan Acute Myeloid Testing Market Revenues & Volume, By Cancer Diagnostic Institutes, 2021- 2031F |
7 Japan Acute Myeloid Testing Market Import-Export Trade Statistics |
7.1 Japan Acute Myeloid Testing Market Export to Major Countries |
7.2 Japan Acute Myeloid Testing Market Imports from Major Countries |
8 Japan Acute Myeloid Testing Market Key Performance Indicators |
8.1 Average turnaround time for AML test results |
8.2 Adoption rate of novel AML testing technologies in Japan |
8.3 Rate of utilization of genetic testing in AML diagnosis |
9 Japan Acute Myeloid Testing Market - Opportunity Assessment |
9.1 Japan Acute Myeloid Testing Market Opportunity Assessment, By Biomarker Type, 2021 & 2031F |
9.2 Japan Acute Myeloid Testing Market Opportunity Assessment, By Product and Service, 2021 & 2031F |
9.3 Japan Acute Myeloid Testing Market Opportunity Assessment, By Technology, 2021 & 2031F |
9.4 Japan Acute Myeloid Testing Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Japan Acute Myeloid Testing Market - Competitive Landscape |
10.1 Japan Acute Myeloid Testing Market Revenue Share, By Companies, 2024 |
10.2 Japan Acute Myeloid Testing Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here